ATNFW - 180 Life Sciences Corp - Warrants (07/11/2025)
Previous close
0.01
0 0%
Share volume: 12,999
Last Updated: Thu 29 Aug 2024 06:00:00 AM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.01
0.00
0.00%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
10.23%
1 Month
-3.00%
3 Months
8.99%
6 Months
67.24%
1 Year
-3.00%
2 Year
-88.52%
Key data
Stock price
$0.01
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.00 - $0.03
52 WEEK CHANGE
-$0.03
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO:
Region: US
Website:
Employees: 5
IPO year: -
Issue type:
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website:
Employees: 5
IPO year: -
Issue type:
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
180 life sciences corp., a clinical-stage biotechnology company, engages in the development of drug candidates in the areas of inflammatory diseases, fibrosis, and pain. its product development platforms in phase iib/iii clinical trials include fibrosis and anti-tnf platform, which focuses on fibrosis and anti-tumor necrosis factors; synthetic cannabidiol (cbd) analogs platform, which are man-made derivatives of cbd; and a7nachr platform, which focuses on alpha 7 nicotinic acetylcholine receptor. the company is headquartered in menlo park, california.
Recent news